Trial record 1 of 1 for:
RLY-2608-101
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05216432 |
|
Recruitment Status :
Recruiting
First Posted : January 31, 2022
Last Update Posted : November 9, 2023
|
Sponsor:
Relay Therapeutics, Inc.
Information provided by (Responsible Party):
Relay Therapeutics, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | January 31, 2025 |
| Estimated Study Completion Date : | August 31, 2025 |